REGN Regeneron Pharmaceuticals, Inc. Stock Quote

REGN [NASD]

Index	S&P 500	P/E	18.93	EPS (ttm)	27.36	Insider Own	1.30%	Shs Outstand	105.50M	Perf Week	3.85%
Market Cap	53.33B	Forward P/E	14.10	EPS next Y	36.73	Insider Trans	-16.10%	Shs Float	101.81M	Perf Month	5.32%
Income	3.16B	PEG	1.70	EPS next Q	8.42	Inst Own	92.20%	Short Float	1.93%	Perf Quarter	-11.49%
Sales	8.24B	P/S	6.47	EPS this Y	-10.80%	Inst Trans	3.75%	Short Ratio	2.14	Perf Half Y	-19.58%
Book/sh	95.98	P/B	5.40	EPS next Y	20.73%	ROA	20.70%	Target Price	664.54	Perf Year	34.33%
Cash/sh	29.39	P/C	17.62	EPS next 5Y	11.14%	ROE	29.80%	52W Range	328.13 - 664.64	Perf YTD	7.21%
Dividend	-	P/FCF	33.70	EPS past 5Y	44.00%	ROI	16.10%	52W High	-22.07%	Beta	0.18
Dividend %	-	Quick Ratio	3.40	Sales past 5Y	22.80%	Gross Margin	88.00%	52W Low	57.85%	ATR	13.34
Employees	8100	Current Ratio	3.90	Sales Q/Q	31.60%	Oper. Margin	37.40%	RSI (14)	61.19	Volatility	2.80% 2.45%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	26.10%	Profit Margin	38.30%	Rel Volume	0.85	Prev Close	517.91
Shortable	Yes	LT Debt/Eq	0.27	Earnings	Nov 05 BMO	Payout	0.00%	Avg Volume	916.27K	Price	517.93
Recom	2.10	SMA20	5.35%	SMA50	1.07%	SMA200	-8.79%	Volume	779,847	Change	0.00%

Jan-13-21

Upgrade

The Benchmark Company

Hold → Buy

$590

Jan-08-21

Upgrade

Citigroup

Neutral → Buy

$635 → $575

Oct-05-20

Upgrade

Cantor Fitzgerald

Neutral → Overweight

$690

Aug-20-20

Downgrade

The Benchmark Company

Buy → Hold

Jul-09-20

Upgrade

SunTrust

Hold → Buy

$400 → $750

May-26-20

Upgrade

Wells Fargo

Equal Weight → Overweight

$559 → $734

Apr-28-20

Downgrade

Citigroup

Buy → Neutral

$540 → $575

Apr-17-20

Upgrade

The Benchmark Company

Hold → Buy

$655

Apr-08-20

Initiated

The Benchmark Company

Hold

Mar-31-20

Initiated

Wolfe Research

Peer Perform

Feb-27-20

Initiated

Barclays

Overweight

$530

Feb-26-20

Upgrade

Canaccord Genuity

Hold → Buy

$550

Feb-26-20

Downgrade

Robert W. Baird

Outperform → Neutral

$410

Feb-25-20

Upgrade

Jefferies

Hold → Buy

$355 → $492

Feb-11-20

Upgrade

Argus

Hold → Buy

$430

Dec-24-19

Initiated

Raymond James

Mkt Perform

Dec-16-19

Downgrade

Evercore ISI

Outperform → In-line

Dec-13-19

Upgrade

Credit Suisse

Neutral → Outperform

$400

Nov-12-19

Initiated

SunTrust

Hold

$360

Nov-07-19

Upgrade

Citigroup

Neutral → Buy

$340 → $420

Jan-14-21 12:10PM	Why Regeneron (REGN) Could Beat Earnings Estimates Again Zacks
Jan-13-21 04:27PM	US STOCKS-S&P closes higher with defensive sectors leading gains Reuters
02:53PM	US STOCKS-Wall St gains steadily while impeachment hearings get underway Reuters
02:29PM	Efficient vaccine rollout is going to depend on individual states and their mandates: Doctor Yahoo Finance Video
02:17PM	Regeneron (REGN), U.S. Government Ink Deal for COVID-19 Treatment Zacks
02:11PM	Biotech Stock Roundup: Updates From REGN, GILD & VIR, CVAC Teams Up With BAYRY Zacks
12:58PM	Is Regeneron Stock Heading to $590? Motley Fool
11:57AM	US STOCKS-S&P 500, Nasdaq tick higher on Intel boost Reuters
10:32AM	CORRECTED-US STOCKS-Wall St flat as stimulus rally cools; Intel shines Reuters
10:00AM	Dow Jones Today, Stocks Mixed Ahead Of Second Trump Impeachment Vote; Intel Spikes On Leadership Change Investor's Business Daily
09:02AM	CORRECTED-US STOCKS-Wall St set to slip as stimulus rally pauses Reuters
08:49AM	Urban Outfitters, General Motors, Twitter - Wednesday's Premarket Movers TheStreet.com
08:47AM	Regeneron Inks Deal to Sell Covid-19 Treatment to U.S., Even as Usage Lags Barrons.com
07:07AM	US STOCKS-Futures tepid after recent run powered by stimulus hopes Reuters
04:10AM	Regeneron To Supply US With Another 1.25M COVID-19 Treatment Doses Benzinga
Jan-12-21 06:28PM	Regeneron in $2.6 Billion Deal For More Doses of COVID Treatment TheStreet.com
06:09PM	Regeneron says U.S. government to buy 1.25 million doses of its COVID-19 treatment MarketWatch
05:45PM	Regeneron Announces U.S. Government Agreement to Purchase Additional COVID-19 Antibody Cocktail Doses PR Newswire
Jan-11-21 09:39AM	Regeneron says COVID-19 antibody therapy will likely help against variants Reuters
08:46AM	Regeneron (REGN) Upgrade Lifts Range-Bound Biotech Stocks Investopedia
Jan-08-21 01:40PM	Regeneron Upgraded to Buy at Citi on Eczema Drug Potential TheStreet.com
09:11AM	Regeneron Stock Has Fallen. Why It Could Be Time to Buy. Barrons.com
09:00AM	Don't Expect Covid-19 Research to Deliver Certainty Bloomberg
Jan-06-21 04:15PM	This Small Gene Therapy Stock Is Taking On Giants Regeneron, Roche Investor's Business Daily
04:36AM	Declining Stock and Solid Fundamentals: Is The Market Wrong About Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)? Simply Wall St.
Jan-05-21 07:08AM	3 Recession-Proof Healthcare Stocks to Buy for 2021 Motley Fool
Jan-03-21 04:37AM	Why Aren't Doctors Prescribing Eli Lilly's and Regeneron's COVID-19 Treatments? Motley Fool
Dec-30-20 11:40AM	Biotech Stock Roundup: REGN Provides COVID-19 Updates, MYOV Partners With PFE & More Zacks
11:34AM	Regeneron (REGN) Releases Initial Data on Cocktail for COVID-19 Zacks
10:23AM	A Look Into Regeneron Pharmaceuticals Price Over Earnings Benzinga
09:28AM	Regenerons Antibodies Appear to Help Hospitalized Patientsand Could Help 2021 Revenue Barrons.com
08:41AM	Regeneron says it will continue trial of COVID antibody cocktail as latest data show positive results MarketWatch
08:08AM	The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data Benzinga
03:30AM	Regeneron COVID-19 Antibody Cocktail Shows Positive Response In Hospitalized Patients Benzinga
Dec-29-20 05:38PM	Regeneron says its COVID-19 antibody therapy showed promise in hospitalized patients Reuters
04:30PM	Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen PR Newswire
Dec-28-20 08:52AM	Russia to test new COVID-19 antibody drug in new year Reuters
Dec-22-20 10:35AM	Roche's (RHHBY) DME Drug Meets Primary Endpoint in Studies Zacks
08:00AM	Better Returns With Less Risk? Goldman Has a Basket of Stocks for That. Barrons.com
Dec-18-20 06:30AM	2 Best Biotech Stocks to Buy in December Motley Fool
Dec-17-20 05:00PM	New England Journal of Medicine Publishes Positive Initial Regeneron Antibody Cocktail Results in Non-hospitalized Patients with COVID-19 PR Newswire
04:21PM	12 Best Large Biotech Stocks to Buy Now Insider Monkey
Dec-16-20 03:30PM	U.S. hospital demand for Lilly, Regeneron COVID-19 antibody drugs 'disappointing' Reuters
07:00AM	Regeneron Announces Presentation at the 39th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-15-20 09:36AM	Regeneron Pharmaceuticals, Inc. -- Moody's announces completion of a periodic review of ratings of Regeneron Pharmaceuticals, Inc. Moody's
07:35AM	Could Regeneron Pharmaceuticals Be a Millionaire-Maker Stock? Motley Fool
06:55AM	Is This Stock On Its Way to Making a COVID-19 Vaccine Obsolete? Motley Fool
Dec-14-20 07:58PM	Is REGN A Good Stock To Buy Now? Insider Monkey
11:14AM	The Zacks Analyst Blog Highlights: Oracle, Adobe, Costco, AutoZone, Regeneron Pharmaceuticals and Bank of New York Mellon Zacks
09:27AM	Analysts Say These 9 Amazing Stocks Are Just Getting Started Investor's Business Daily Video
Dec-11-20 05:50PM	Regeneron (REGN) Gains As Market Dips: What You Should Know Zacks
07:17AM	3 Top Growth Stocks to Buy Right Now Motley Fool
06:50AM	2 Best Coronavirus Stocks to Buy Right Now Motley Fool
Dec-09-20 08:00AM	9 Amazing Stocks Are Just Getting Started, Analysts Say Investor's Business Daily
Dec-08-20 01:09PM	Vaccines Alone Arent Enough to Beat Covid-19 Bloomberg
Dec-07-20 12:40PM	Race for Multiple Myeloma Drugs Not Moving Stocks Yet Barrons.com
11:46AM	Regeneron (REGN) Posts Upbeat Data on Myeloma Candidate at ASH Zacks
05:19AM	Regeneron Pharmaceuticals (NASDAQ:REGN) Shareholders Have Enjoyed A 32% Share Price Gain Simply Wall St.
Dec-05-20 05:00PM	Regeneron's BCMAxCD3 Bispecific Antibody (REGN5458) Shows Deep and Durable Responses in Patients with Heavily-pretreated Multiple Myeloma in Phase 1 PR Newswire
11:32AM	Regeneron (REGN) Down 16.4% Since Last Earnings Report: Can It Rebound? Zacks
Dec-04-20 04:49PM	3 Best ETF Picks: Megatrends To Invest In Now Investor's Business Daily
04:21PM	Dont Chase the Rebound in Sorrento Its Not Worth the Risk InvestorPlace
Dec-03-20 07:10AM	Lilly (LLY) to Supply More Doses of COVID-19 Antibody to US Zacks
Dec-02-20 01:11PM	Scott+Scott Attorneys at Law LLP Continues Investigation of Regeneron Pharmaceuticals, Inc.s Directors and Officers for Breach of Fiduciary Duty REGN Business Wire
Dec-01-20 04:55PM	Activist Shareholders Press Pfizer, J&J, and Other Pharma Companies on Covid Vaccine Price and Access Barrons.com
02:23PM	New Advances in Treating Difficult Blood Cancers From Johnson & Johnson and Others Barrons.com
Nov-30-20 02:39PM	Regeneron (REGN), Sanofi Win EC Nod for Dupixent Label Expansion Zacks
08:54AM	2 Biotech Funds Poised for a Healthy Breakout Investopedia
07:00AM	Regeneron Announces Investor Webcast at American Society of Hematology 2020 Annual Meeting PR Newswire
01:28AM	Sanofi and Regeneron's Dupixent wins EU approval to treat children Reuters
12:59AM	Dupixent® (dupilumab) Approved by European Commission as First and Only Biologic Medicine for Children Aged 6 to 11 Years with Severe Atopic Dermatitis PR Newswire
Nov-27-20 10:54AM	Is Regeneron Pharmaceuticals (REGN) a Worthy Stock Now? Zacks
Nov-25-20 01:16PM	Biotech Stock Roundup: REGN's Cocktail Gets EUA, GILD & AMGN Provide Updates & More Zacks
09:08AM	Alnylam (ALNY) Gets FDA Nod for Oxlumo to Treat Renal Disease Zacks
Nov-24-20 03:12PM	Regeneron's (REGN) Cocktail Gets EUA for COVID-19 by FDA Zacks
09:50AM	Roche (RHHBY) Gets FDA Nod for Influenza Drug Label Expansion Zacks
09:47AM	Vir Biotech CEO Says His Covid-19 Medicine Offers Promise for Next Outbreak Bloomberg
08:58AM	Morning Bell With Jim Cramer: Reviewing the Merck Acquisition TheStreet.com
03:08AM	Regeneron Nears Chart Support After Antibody Cocktail Approval FX Empire
Nov-23-20 05:24PM	U.S. Markets Rise on Vaccine Optimism Investopedia
04:42PM	Dow Jones Surges More Than 300 Points, Led By Boeing, Walt Disney, Chevron; What's Wrong With Apple Stock? Investor's Business Daily
04:13PM	AstraZeneca Dives On Covid Vaccine News, Buoying Moderna, BioNTech Investor's Business Daily
04:06PM	'We still have a major problem with outpatient testing': Dr. Amesh Adalja Yahoo Finance Video
11:12AM	Coronavirus update: FDA OKs Regeneron antibody EUA; AstraZeneca shows positive vaccine results Yahoo Finance
10:41AM	Looking Into Regeneron Pharmaceuticals's Return On Capital Employed Benzinga
10:38AM	Regeneron Is Allowed to Sell the Covid Antibody It Served Trump and the Stock Is Rising Barrons.com
10:20AM	Vaccine news latest: Oxford-AstraZeneca promising results, FDA authorizes Regenerons treatment Yahoo Finance Video
09:58AM	Dow Jones Today, Stocks Open Higher; Merck, Regeneron Jump On Covid News; Tesla Nails A Breakout Investor's Business Daily
09:56AM	Heres When the First Americans Could Get a Coronavirus Vaccine Barrons.com
09:48AM	Regeneron Spikes After FDA Approval For COVID Therapy Used To Treat President Trump TheStreet.com
06:33AM	Vaccine, AstraZeneca, Tesla, Regeneron - 5 Things You Must Know Monday TheStreet.com
Nov-22-20 03:21PM	Regeneron Covid Drug Gets Emergency OK TheStreet.com
10:53AM	Regeneron's Coronavirus Treatment Becomes First Antibody Cocktail to Earn Emergency Use Authorization from FDA Motley Fool
09:54AM	Regeneron antibody cocktail wins emergency-use authorization from FDA MarketWatch
09:07AM	Regeneron's COVID Treatment Gets Emergency FDA Approval Benzinga
07:05AM	3 Best Pharma Stocks to Buy Right Now Motley Fool
Nov-21-20 07:56PM	Regeneron's REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization PR Newswire
07:28AM	Is There Room for Latecomers to the COVID-19 Party? Motley Fool
Nov-20-20 10:08AM	Alnylam (ALNY) Gets EU Nod for Oxlumo to Treat Renal Disease Zacks
Nov-18-20 12:16PM	RedHill (RDHL) to Begin Study on Second Coronavirus Candidate Zacks

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RYAN ARTHUR F	Director	Jan 04	Sale	483.60	100	48,360	23,543	Jan 05 04:09 PM
YANCOPOULOS GEORGE	President and Chief Scientific	Dec 30	Option Exercise	52.03	398,079	20,712,050	908,303	Dec 31 05:30 PM
RYAN ARTHUR F	Director	Dec 01	Sale	520.48	100	52,048	23,643	Dec 02 04:09 PM
MURPHY ANDREW J	EVP Research	Nov 17	Sale	542.73	6,628	3,597,188	47,136	Nov 18 04:02 PM
MURPHY ANDREW J	EVP Research	Nov 16	Option Exercise	30.63	13,736	420,734	60,872	Nov 18 04:02 PM
COLES N ANTHONY	Director	Nov 13	Option Exercise	345.47	11	3,800	654	Nov 13 05:57 PM
RYAN ARTHUR F	Director	Nov 02	Sale	548.54	100	54,854	23,743	Nov 03 05:22 PM
MURPHY ANDREW J	EVP Research	Oct 22	Option Exercise	38.56	5,185	199,926	47,136	Oct 23 04:02 PM
McCourt Marion	SVP Commercial	Oct 05	Option Exercise	342.93	1,000	342,930	14,963	Oct 06 04:07 PM
GOLDSTEIN JOSEPH L	Director	Oct 05	Option Exercise	520.01	9,212	4,790,332	14,855	Oct 06 04:09 PM
McCourt Marion	SVP Commercial	Oct 05	Sale	600.00	1,000	600,000	13,963	Oct 06 04:07 PM
GOLDSTEIN JOSEPH L	Director	Oct 05	Sale	600.00	9,212	5,527,200	5,643	Oct 06 04:09 PM
RYAN ARTHUR F	Director	Oct 01	Sale	558.13	100	55,813	28,343	Oct 05 04:13 PM
BROWN MICHAEL S	Director	Sep 22	Option Exercise	378.77	5,090	1,927,917	5,733	Sep 23 04:01 PM
BROWN MICHAEL S	Director	Sep 22	Sale	552.36	1,000	552,360	9,349	Sep 23 04:01 PM
BROWN MICHAEL S	Director	Sep 22	Sale	552.36	5,090	2,811,512	643	Sep 23 04:01 PM
GOLDSTEIN JOSEPH L	Director	Sep 22	Sale	552.36	20	11,047	5,643	Sep 23 04:00 PM
GOLDSTEIN JOSEPH L	Director	Sep 21	Option Exercise	376.76	16,574	6,244,372	22,217	Sep 23 04:00 PM
GOLDSTEIN JOSEPH L	Director	Sep 21	Sale	549.86	16,554	9,102,446	5,663	Sep 23 04:00 PM
RYAN ARTHUR F	Director	Sep 01	Sale	604.58	100	60,458	28,443	Sep 03 04:18 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Aug 31	Sale	615.04	4,672	2,873,467	14,438	Aug 31 04:37 PM
SING GEORGE L	Director	Aug 31	Sale	612.06	10,000	6,120,555	54,415	Aug 31 04:36 PM
POON CHRISTINE A	Director	Aug 28	Option Exercise	28.44	40,000	1,137,550	41,433	Aug 31 04:35 PM
POON CHRISTINE A	Director	Aug 28	Sale	601.22	40,000	24,048,715	1,433	Aug 31 04:35 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Aug 27	Option Exercise	52.03	10,000	520,300	21,241	Aug 31 04:37 PM
SING GEORGE L	Director	Aug 25	Option Exercise	273.67	12,750	3,489,293	97,165	Aug 27 04:23 PM
Van Plew Daniel P	EVP & General Mgr Industrial O	Aug 25	Sale	610.89	27,109	16,560,738	20,001	Aug 27 04:21 PM
SING GEORGE L	Director	Aug 25	Sale	612.00	1,000	612,000	3,700	Aug 27 04:23 PM
SING GEORGE L	Director	Aug 25	Sale	607.28	32,750	19,888,518	64,415	Aug 27 04:23 PM
SING GEORGE L	Director	Aug 24	Option Exercise	177.82	10,037	1,784,779	104,452	Aug 24 06:13 PM
SING GEORGE L	Director	Aug 24	Sale	593.63	20,037	11,894,577	84,415	Aug 24 06:13 PM
SING GEORGE L	Director	Aug 21	Option Exercise	117.24	9,963	1,168,071	114,078	Aug 24 06:13 PM
SING GEORGE L	Director	Aug 21	Sale	605.12	19,963	12,080,040	94,415	Aug 24 06:13 PM
GOLDSTEIN JOSEPH L	Director	Aug 21	Sale	617.18	1,000	617,180	5,643	Aug 24 05:19 PM
Van Plew Daniel P	EVP & General Mgr Industrial O	Aug 20	Option Exercise	179.13	75,000	13,434,750	95,001	Aug 24 04:47 PM
SING GEORGE L	Director	Aug 20	Option Exercise	57.11	10,000	571,100	114,415	Aug 24 06:13 PM
McCourt Marion	SVP Commercial	Aug 20	Option Exercise	342.93	1,000	342,930	14,963	Oct 06 04:07 PM
SING GEORGE L	Director	Aug 20	Sale	616.91	21,000	12,955,042	104,415	Aug 24 06:13 PM
McCourt Marion	SVP Commercial	Aug 20	Sale	612.15	1,000	612,150	13,963	Oct 06 04:07 PM
VAGELOS P ROY	Director	Aug 11	Sale	602.94	33,460	20,174,355	50,192	Aug 13 04:02 PM
Landry Robert E	EVP Finance CFO	Aug 04	Sale	654.46	696	455,504	23,973	Aug 05 05:07 PM
RYAN ARTHUR F	Director	Aug 03	Sale	641.93	100	64,193	28,543	Aug 05 05:09 PM
Landry Robert E	EVP Finance CFO	Jul 21	Sale	647.58	391	253,204	24,669	Jul 22 04:30 PM
Fenimore Christopher R.	VP Controller	Jul 21	Sale	642.04	3,709	2,381,317	17,501	Jul 22 04:31 PM
Fenimore Christopher R.	VP Controller	Jul 20	Option Exercise	156.01	12,224	1,907,015	25,277	Jul 22 04:31 PM
Landry Robert E	EVP Finance CFO	Jul 20	Option Exercise	491.43	8,500	4,177,160	29,671	Jul 22 04:30 PM
MURPHY ANDREW J	EVP Research	Jul 14	Sale	633.48	2,380	1,507,677	41,951	Jul 15 04:51 PM
MURPHY ANDREW J	EVP Research	Jul 14	Sale	623.89	3,929	2,451,277	44,331	Jul 15 04:51 PM
Landry Robert E	EVP Finance CFO	Jul 14	Sale	640.50	579	370,850	23,973	Jul 14 04:17 PM
MURPHY ANDREW J	EVP Research	Jul 13	Option Exercise	30.63	13,000	398,190	54,951	Jul 15 04:51 PM
MURPHY ANDREW J	EVP Research	Jul 13	Sale	628.50	8,000	5,028,022	41,951	Jul 15 04:51 PM
Landry Robert E	EVP Finance CFO	Jul 09	Option Exercise	399.66	3,000	1,198,980	26,973	Jul 13 04:28 PM
Landry Robert E	EVP Finance CFO	Jul 08	Sale	639.66	1,160	742,011	23,973	Jul 09 04:29 PM
SING GEORGE L	Director	Jul 07	Option Exercise	33.42	7,500	250,650	122,915	Jul 08 04:16 PM
Zoghbi Huda Y	Director	Jul 07	Option Exercise	391.92	1,706	668,616	2,349	Jul 08 04:14 PM
Landry Robert E	EVP Finance CFO	Jul 07	Option Exercise	524.47	12,500	6,555,850	33,973	Jul 09 04:29 PM
SING GEORGE L	Director	Jul 07	Sale	650.16	3,000	1,950,474	400	Jul 08 04:16 PM
SING GEORGE L	Director	Jul 07	Sale	650.00	7,500	4,875,000	115,415	Jul 08 04:16 PM
Zoghbi Huda Y	Director	Jul 07	Sale	650.00	1,706	1,108,900	643	Jul 08 04:14 PM
BROWN MICHAEL S	Director	Jul 01	Option Exercise	413.33	3,613	1,493,361	4,256	Jul 02 04:02 PM
BROWN MICHAEL S	Director	Jul 01	Sale	607.62	3,613	2,195,342	643	Jul 02 04:02 PM
RYAN ARTHUR F	Director	Jul 01	Sale	609.70	100	60,970	28,643	Jul 02 04:01 PM
Landry Robert E	EVP Finance CFO	Jun 29	Sale	612.57	400	245,029	23,973	Jun 30 04:02 PM
SING GEORGE L	Director	Jun 29	Sale	608.91	3,000	1,826,721	1,400	Jun 29 04:08 PM
Landry Robert E	EVP Finance CFO	Jun 23	Sale	631.27	512	323,212	24,373	Jun 24 04:03 PM
Landry Robert E	EVP Finance CFO	Jun 22	Option Exercise	555.67	8,900	4,945,463	33,273	Jun 24 04:03 PM
Bassler Bonnie L	Director	Jun 19	Option Exercise	391.92	2,559	1,002,923	3,202	Jun 22 04:18 PM
Bassler Bonnie L	Director	Jun 19	Sale	630.02	2,559	1,612,211	643	Jun 22 04:18 PM
Fenimore Christopher R.	VP Controller	Jun 16	Sale	590.89	3,556	2,101,215	15,277	Jun 17 04:02 PM
Fenimore Christopher R.	VP Controller	Jun 15	Option Exercise	47.07	9,406	442,742	20,323	Jun 17 04:02 PM
Zoghbi Huda Y	Director	Jun 11	Option Exercise	391.92	1,706	668,616	2,349	Jun 12 04:03 PM
Zoghbi Huda Y	Director	Jun 11	Sale	625.00	1,706	1,066,250	643	Jun 12 04:03 PM
Landry Robert E	EVP Finance CFO	Jun 11	Sale	612.08	988	604,731	24,373	Jun 12 04:01 PM
Landry Robert E	EVP Finance CFO	Jun 10	Option Exercise	272.70	3,500	954,450	27,873	Jun 12 04:01 PM
Zoghbi Huda Y	Director	Jun 10	Option Exercise	391.92	1,706	668,616	2,349	Jun 12 04:03 PM
Zoghbi Huda Y	Director	Jun 10	Sale	610.24	1,706	1,041,068	643	Jun 12 04:03 PM
Landry Robert E	EVP Finance CFO	Jun 09	Sale	608.01	4,271	2,596,792	24,373	Jun 10 04:04 PM
GOLDSTEIN JOSEPH L	Director	Jun 08	Option Exercise	413.33	10,838	4,479,671	17,481	Jun 09 04:05 PM
Landry Robert E	EVP Finance CFO	Jun 08	Option Exercise	272.70	15,500	4,226,850	29,860	Jun 10 04:04 PM
GOLDSTEIN JOSEPH L	Director	Jun 08	Sale	592.95	10,838	6,426,362	6,643	Jun 09 04:05 PM
Bassler Bonnie L	Director	Jun 05	Option Exercise	391.92	2,559	1,002,923	3,202	Jun 05 04:15 PM
Bassler Bonnie L	Director	Jun 05	Sale	600.00	2,559	1,535,400	643	Jun 05 04:15 PM
RYAN ARTHUR F	Director	Jun 01	Sale	603.23	100	60,323	28,743	Jun 02 04:04 PM
SING GEORGE L	Director	May 29	Sale	596.51	1,000	596,510	2,400	Jun 01 04:08 PM
GOLDSTEIN JOSEPH L	Director	May 28	Sale	578.94	1,000	578,940	6,643	Jun 01 04:02 PM
SING GEORGE L	Director	May 28	Sale	579.00	1,000	579,000	2,900	Jun 01 04:08 PM
VAGELOS P ROY	Chairman of the Board	May 21	Sale	577.49	783	452,178	307,749	May 22 06:21 PM
VAGELOS P ROY	Chairman of the Board	May 21	Sale	564.37	148,811	83,984,786	308,532	May 22 06:21 PM
VAGELOS P ROY	Chairman of the Board	May 20	Option Exercise	30.63	312,500	9,571,875	497,063	May 22 06:21 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	May 15	Sale	572.00	8,380	4,793,360	14,438	May 15 04:03 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	May 14	Option Exercise	59.20	18,311	1,084,011	32,749	May 15 04:03 PM
SING GEORGE L	Director	May 13	Option Exercise	33.42	5,000	167,100	120,415	May 13 09:00 PM
SING GEORGE L	Director	May 13	Sale	580.00	5,000	2,900,000	115,415	May 13 09:00 PM
SCHLEIFER LEONARD S	President & CEO	May 12	Sale	569.22	150,922	85,908,042	474,499	May 13 09:01 PM
SCHLEIFER LEONARD S	President & CEO	May 11	Option Exercise	30.63	312,500	9,571,875	722,368	May 13 09:01 PM
SING GEORGE L	Director	May 11	Sale	575.00	850	488,750	2,150	May 13 09:00 PM
STAHL NEIL	EVP Research and Development	May 11	Sale	569.52	5,305	3,021,289	11,380	May 11 04:39 PM
STAHL NEIL	EVP Research and Development	May 08	Option Exercise	52.03	12,500	650,375	23,880	May 11 04:39 PM
Zoghbi Huda Y	Director	May 07	Option Exercise	391.92	5,118	2,005,847	5,761	May 08 04:03 PM
Zoghbi Huda Y	Director	May 07	Sale	566.52	5,118	2,899,461	643	May 08 04:03 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience